HealthQuill China life sciences
AstraZeneca’s drug for treating limited-stage small cell lung cancer got a recommendation for approval from an EU regulator panel, according to the British-Swedish drugmaker.
Pharma

AstraZeneca to invest $2.5 Billion in Beijing R&D hub, expands China presence

HQ Team March 21, 2025: AstraZeneca has announced a $2.5 billion investment in a new Beijing R&D center, partnerships with Harbour BioMed and.

Read More